Molecular Partners AG operates as a clinical-stage biopharmaceutical company.
Excellent balance sheet with high growth potential.
Share Price & News
How has Molecular Partners's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MOLN's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: MOLN exceeded the Swiss Biotechs industry which returned 4.1% over the past year.
Return vs Market: MOLN exceeded the Swiss Market which returned 1.9% over the past year.
Price Volatility Vs. Market
How volatile is Molecular Partners's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StCan We See Significant Insider Ownership On The Molecular Partners AG (VTX:MOLN) Share Register?
2 months ago | Simply Wall StShould You Be Pleased About The CEO Pay At Molecular Partners AG's (VTX:MOLN)
3 months ago | Simply Wall StWhen Can We Expect A Profit From Molecular Partners AG (VTX:MOLN)?
Is Molecular Partners undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MOLN (CHF21.25) is trading below our estimate of fair value (CHF53.96)
Significantly Below Fair Value: MOLN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MOLN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: MOLN is unprofitable, so we can't compare its PE Ratio to the Swiss market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MOLN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MOLN is overvalued based on its PB Ratio (8.5x) compared to the CH Biotechs industry average (1.7x).
How is Molecular Partners forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MOLN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.2%).
Earnings vs Market: MOLN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MOLN's is expected to become profitable in the next 3 years.
Revenue vs Market: MOLN's revenue (20.5% per year) is forecast to grow faster than the Swiss market (2.4% per year).
High Growth Revenue: MOLN's revenue (20.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MOLN's Return on Equity is forecast to be low in 3 years time (0.9%).
How has Molecular Partners performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MOLN is currently unprofitable.
Growing Profit Margin: MOLN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MOLN is unprofitable, and losses have increased over the past 5 years at a rate of -39.5% per year.
Accelerating Growth: Unable to compare MOLN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MOLN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).
Return on Equity
High ROE: MOLN has a negative Return on Equity (-67.03%), as it is currently unprofitable.
How is Molecular Partners's financial position?
Financial Position Analysis
Short Term Liabilities: MOLN's short term assets (CHF99.9M) exceed its short term liabilities (CHF28.6M).
Long Term Liabilities: MOLN's short term assets (CHF99.9M) exceed its long term liabilities (CHF22.2M).
Debt to Equity History and Analysis
Debt Level: MOLN is debt free.
Reducing Debt: MOLN has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MOLN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MOLN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Molecular Partners's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MOLN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MOLN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MOLN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MOLN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MOLN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Patrick Amstutz (44yo)
Dr. Patrick Amstutz, Ph.D. is a Co-Founder of Molecular Partners AG and has been its Chief Executive Officer since November 2016 and serves as its Member of Management Board. Dr. Amstutz served as Acting C ...
CEO Compensation Analysis
Compensation vs Market: Patrick's total compensation ($USD961.79K) is about average for companies of similar size in the Swiss market ($USD966.94K).
Compensation vs Earnings: Patrick's compensation has increased whilst the company is unprofitable.
|Co-Founder||16.33yrs||no data||3.47% CHF16.0m|
|CFO & Member of Management Board||13.08yrs||no data||1.1% CHF5.1m|
|Chief Medical Officer & Member of Management Board||0.67yr||no data||no data|
|Vice President of Technology||no data||no data||no data|
|Senior Vice President of Investor Relations||no data||no data||no data|
|General Counsel||3.83yrs||no data||no data|
|Vice President of Human Resources||1.08yrs||no data||no data|
|Senior Vice President of Development||1.08yrs||no data||no data|
|Senior Vice President of Oncology Research||1.08yrs||no data||no data|
Experienced Management: MOLN's management team is considered experienced (2.3 years average tenure).
|Non Executive Director||6.33yrs||CHF109.00k||0.018% CHF82.5k|
|Chairman of the Board||2.08yrs||CHF327.00k||no data|
|Director||0.083yr||no data||no data|
|Director||0.083yr||no data||no data|
|Director||0.083yr||no data||no data|
Experienced Board: MOLN's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.
Molecular Partners AG's company bio, employee growth, exchange listings and data sources
- Name: Molecular Partners AG
- Ticker: MOLN
- Exchange: SWX
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF461.971m
- Shares outstanding: 21.74m
- Website: https://www.molecularpartners.com
Number of Employees
- Molecular Partners AG
- Wagistrasse 14
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MOLN||SWX (SIX Swiss Exchange)||Yes||Registered Shares||CH||CHF||Nov 2014|
|0QXX||LSE (London Stock Exchange)||Yes||Registered Shares||GB||CHF||Nov 2014|
|6ML||DB (Deutsche Boerse AG)||Yes||Registered Shares||DE||EUR||Nov 2014|
|MLLC.F||OTCPK (Pink Sheets LLC)||Yes||Registered Shares||US||USD||Nov 2014|
Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0250 that binds and inhibit vascular endothelial growth factor and hepatocyte growth factor pathways, which restores clinical sensitivity to various standard-of-care therapies in multiple myeloma. The company is also developing MP0274 that is in Phase I clinical trials for HER2-positive solid tumors; MP0310, which is in Phase I clinical trials for immuno-oncology; MPO317, a tumor-localized immune agonist that activates immune cells in the tumor; and Peptide-MHC, a tumor-localized immune-cell agonist to attack tumors. It has strategic partnerships with Allergan, Inc. and Amgen SA. Molecular Partners AG was founded in 2004 and is headquartered in Schlieren, Switzerland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/27 04:58|
|End of Day Share Price||2020/05/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.